Study: The biology of PMDD
A recent study, published in March 2026 in the Journal of Affective Disorders, provides a great overview of the science, psychiatric burden, and treatment landscape of PMDD. Its synthesis of the pathophysiology of PMDD is particularly valuable and points to how much more research is needed.
The authors frame PMDD as a multi-system condition involving:
Ovarian hormone fluctuations, especially in the luteal phase
Altered sensitivity to progesterone’s metabolite allopregnanolone / ALLO
GABA-A receptor dysregulation
Serotonin disruption
Genetic polymorphisms affecting estrogen, serotonin, and GABA pathways
Psychosocial risk factors such as trauma, chronic stress, diet, BMI, and lifestyle
Deep dive: What the study says is happening biologically
Women and girls with PMDD have an abnormal brain sensitivity to normal cyclical hormone changes, especially during the luteal phase. While the menstrual cycle is the trigger, the problem appears to be the brain’s neurochemical response to that trigger.
Progesterone and allopregnanolone: The main trigger
The review places progesterone at the center of PMDD pathophysiology. After ovulation, progesterone rises during the luteal phase. Progesterone is then metabolized into allopregnanolone, often abbreviated ALLO, a neuroactive steroid that crosses the blood-brain barrier and affects mood-regulating circuits.
In many people, ALLO has a calming effect because it positively modulates GABA-A receptors, which are part of the brain’s main inhibitory system. But in PMDD, the review argues that this system may become maladaptive: normal luteal-phase progesterone and ALLO fluctuations can produce irritability, anxiety, dysphoria, emotional reactivity, and impaired regulation, rather than calm.
The crucial point: PMDD may reflect altered receptor sensitivity, not simply abnormal hormone concentration. The review notes that research often assumes women have uniform ALLO–GABA-A sensitivity, but pilot data suggest substantial individual variability in receptor and neurosteroid responses. One cited pilot study involved only n = 10, underscoring that this area is promising but still underdeveloped.
GABA-A receptor dysregulation: Why a “calming” hormone can feel destabilizing
GABA is the brain’s major inhibitory neurotransmitter. It normally helps reduce neuronal excitability and stabilize mood, tension, and arousal. ALLO usually enhances GABA-A receptor activity. But the review highlights a paradox in PMDD: ALLO’s interaction with GABA-A receptors may contribute to worsened anxiety and mood symptoms during the luteal phase.
The paper specifically points to altered GABA-A receptor subunit sensitivity, especially involving α4β2δ receptor configurations. This matters because different GABA-A receptor subunits can change how the brain responds to ALLO. In PMDD, the same neurosteroid signal that should be anxiolytic may instead become destabilizing.
This is also why sepranolone / UC1010 (see “PMDD treatments you haven’t heard of”) is biologically interesting. It is described as a GABA-A-modulating steroid antagonist that appears to work by blocking ALLO’s effects during the luteal phase. That therapeutic logic supports the biological hypothesis: if blocking ALLO improves symptoms, then ALLO sensitivity is likely central to at least some PMDD cases.
Estrogen and serotonin: The mood-regulation axis
The review also emphasizes estrogen, especially estradiol, as a regulator of emotional processing. Lower estradiol levels may impair mood regulation through the dorsolateral prefrontal cortex, a brain region involved in executive control and emotional regulation. The authors state that women with low estrogen levels may be more susceptible to PMDD symptoms.
Estrogen also intersects with serotonin. The review describes several serotonin-related abnormalities in PMDD, including: disrupted or depleted serotonin signaling; increased monoamine oxidase-A activity, which can break down serotonin; altered serotonin receptor stimulation; acute tryptophan depletion worsening PMDD symptoms; changes in serotonin transporter availability.
In plain English: estrogen helps regulate serotonin availability. When estrogen drops or fluctuates, serotonin signaling may become less stable. In a vulnerable brain, this may translate into depression, irritability, anxiety, and suicidality.
MAO-A and tryptophan: Why serotonin may dip at the worst time
The study gives special attention to monoamine oxidase-A, or MAO-A, an enzyme involved in breaking down serotonin and other monoamines. Elevated progesterone combined with reduced estrogen may increase MAO-A activity, which can reduce serotonin availability and thereby reduce serotonin receptor stimulation.
The review also notes that acute tryptophan depletion can intensify PMDD symptoms. Tryptophan is the precursor needed to make serotonin. So if tryptophan availability drops, serotonin synthesis may fall, worsening mood instability. This mechanism helps explain why PMDD symptoms can look like depression but are temporally tied to the menstrual cycle.
Genetics: PMDD vulnerability may be partly inherited or molecularly patterned
The review discusses several genes that may influence susceptibility. These include ESR1, SRD5A1, GABRA4, GABRB2, SERT, BDNF, HTR1A, and possibly vitamin D receptor variants. The study’s deeper implication is that PMDD is likely not one uniform disease. It may be a syndrome with multiple biological subtypes: one woman’s PMDD may be more ALLO/GABA driven; another’s may be more serotonin/estrogen driven; another’s may involve immune, stress-axis, or genetic vulnerability.
Brain circuitry: PMDD affects emotional control, not just mood
The review connects PMDD to several brain regions and circuits involved in emotional regulation, including the dorsolateral prefrontal cortex, fronto-cingulate cortex, amygdala, hippocampus, and insula.
The paper notes that frontal alpha asymmetry may differ during the luteal phase and that BDNF-related changes may reduce fronto-cingulate responsiveness. It also cites evidence that reduced GABA is associated with negative mood through effects on the amygdala and hippocampus.
This matters because it moves PMDD away from a vague “moodiness” frame. The biology described is about impaired coordination between hormone-sensitive brain circuits that regulate threat detection, emotional salience, impulse control, memory, and mood stabilization.
Immune changes: The luteal phase may alter inflammatory vulnerability
One of the more interesting parts of the review is its discussion of immune cycling. During the luteal phase, progesterone shifts the immune system toward a pregnancy-compatible state. The review says this involves increased Th2 differentiation and secretion of IL-4, IL-5, and IL-10, while inhibiting IL-2 and IFN-γ pathways. The result is reduced NK cell activity, cytotoxic T-cell function, and macrophage phagocytosis. Estrogen may also suppress IFN-γ production.
This does not prove that inflammation “causes” PMDD. But it suggests that menstrual-cycle immune shifts may interact with hormone-sensitive brain systems. The review also notes that obesity may worsen symptoms through inflammatory cytokines released by visceral fat.
Stress, trauma, and the HPA axis: Biology shaped by lived experience
The review repeatedly argues that PMDD cannot be explained by hormones alone. Trauma, chronic stress, diet, lifestyle, BMI, and social context may shape symptom severity through biological systems such as the HPA axis, cortisol rhythms, hippocampal structure, beta-endorphins, and inflammatory signaling.
Childhood trauma and chronic stress are associated with altered HPA-axis reactivity. Stress-related reductions in beta-endorphins and cortisol may intensify emotional dysregulation. High caffeine, sugar, and processed-food intake are linked with worse symptoms, while physical activity may be protective through effects on neurotransmitters and hormones.
The important nuance is that these are not presented as “lifestyle causes” of PMDD. Rather, they are modifiers of a biological vulnerability.
More study needed on PMDD subtypes
The most important unresolved question is whether PMDD is one disease or several biologically distinct subtypes. The authors explicitly call for longitudinal studies, neuroimaging, PET, genomics, transcriptomics, proteomics, and better genotype-phenotype mapping to identify biomarkers and personalize treatment.
Summary of the biology of PMDD
PMDD appears to emerge when normal luteal-phase ovarian hormone changes collide with an unusually sensitive neurobiological system. Progesterone and ALLO affect GABA-A receptors; estrogen affects serotonin and emotional regulation; serotonin transporter dynamics shift across the cycle; genetic variants may alter receptor sensitivity; immune and opioid systems may amplify symptoms; and trauma/stress may sensitize the entire system.
READ THE STUDY: Jerin Sultana, Ashish Ranjan Sharma, Sadia Tabassum Soha, Garima Sharma, Subrata Banik, Afroza Parvin, Md. Ibrahim Khalil, Md. Ashraful Hasan, Mohammad Mahfuz Ali Khan Shawan, “Updated insight into the pathophysiology of premenstrual dysphoric disorder and therapeutic approaches,” Journal of Affective Disorders, Volume 405, 2026 https://doi.org/10.1016/j.jad.2026.121593.
